Published in Hum Vaccin Immunother on January 01, 2014
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model. BMC Genomics (2015) 0.88
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. J Virol (2015) 0.83
Distinct roles of vaccinia virus NF-kB inhibitor proteins A52, B15 and K7 in the immune response. J Virol (2017) 0.75
Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators. Vaccine (2016) 0.75
Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression. Front Immunol (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A (1982) 7.81
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol (1985) 5.77
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques (1997) 3.74
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol (2003) 3.16
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med (2010) 2.53
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A (1993) 2.44
Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A (2008) 2.43
HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet (2004) 2.36
Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci U S A (2003) 2.20
Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin (2010) 2.12
Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun (2009) 2.08
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One (2014) 1.97
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med (2014) 1.87
Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine (1996) 1.86
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol (2005) 1.75
Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A (2010) 1.72
The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res (2009) 1.67
Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J Immunol (2007) 1.66
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine (2008) 1.62
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A (2011) 1.55
Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One (2007) 1.52
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis (2011) 1.48
Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol (2007) 1.46
Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med (2007) 1.44
Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol (2013) 1.41
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine (2006) 1.37
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28
Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol (2004) 1.28
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine (2008) 1.25
MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther (2011) 1.24
Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One (2008) 1.23
Expression profiling of the intermediate and late stages of poxvirus replication. J Virol (2011) 1.20
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One (2010) 1.20
Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur J Immunol (2009) 1.18
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci U S A (1998) 1.16
LC16m8: an attenuated smallpox vaccine. Vaccine (2006) 1.16
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One (2010) 1.15
Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS (2010) 1.14
Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol (2013) 1.12
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One (2011) 1.10
Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA (2009) 1.10
IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol (1999) 1.08
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs (2008) 1.08
Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J Virol (2007) 1.07
Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol (2010) 1.07
A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology (2001) 1.07
Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol Ther (2012) 1.06
Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine (2013) 1.06
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol (2011) 1.06
Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin Biol Ther (2014) 1.05
Improved NYVAC-based vaccine vectors. PLoS One (2011) 1.04
Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine (2007) 1.04
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med (2009) 1.03
Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol (2007) 1.02
Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine (2007) 1.02
Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One (2012) 1.01
Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol (2010) 1.01
Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00
Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses. Clin Vaccine Immunol (2008) 1.00
Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J Immunol (2009) 0.99
Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine (2008) 0.98
Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines (2011) 0.98
Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol (2012) 0.98
A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol (2014) 0.97
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One (2012) 0.96
Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. J Virol (2013) 0.95
Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines (2013) 0.95
Oncolytic myxoma virus: the path to clinic. Vaccine (2013) 0.95
A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One (2009) 0.95
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen. PLoS One (2014) 0.94
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS One (2012) 0.93
Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS One (2013) 0.92
CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Ther (2013) 0.91
Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res (2001) 0.91
Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. Clin Cancer Res (2004) 0.90
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog (2009) 2.24
Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J Virol (2003) 1.97
Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol (2002) 1.94
Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev (2006) 1.94
Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68
The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res (2009) 1.67
Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol (2004) 1.65
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther (2008) 1.57
Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog (2008) 1.57
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A (2011) 1.55
ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS Pathog (2013) 1.51
Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS One (2012) 1.43
TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol (2004) 1.40
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine (2006) 1.37
Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol (2006) 1.35
Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J Virol (2006) 1.26
Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol (2002) 1.26
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine (2008) 1.25
MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther (2011) 1.24
Human cytomegalovirus final envelopment on membranes containing both trans-Golgi network and endosomal markers. Cell Microbiol (2009) 1.23
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One (2010) 1.20
Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol (2005) 1.19
Resistance to viral infection of super p53 mice. Oncogene (2005) 1.17
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene (2002) 1.15
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One (2010) 1.15
Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS (2010) 1.14
The ESCRT machinery is not required for human cytomegalovirus envelopment. Cell Microbiol (2007) 1.13
Vaccinia virus induces apoptosis of infected macrophages. J Gen Virol (2002) 1.12
Cryo-X-ray tomography of vaccinia virus membranes and inner compartments. J Struct Biol (2009) 1.11
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One (2011) 1.10
A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J (2010) 1.07
A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine (2002) 1.06
Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cell Microbiol (2007) 1.06
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol (2011) 1.06
Improved NYVAC-based vaccine vectors. PLoS One (2011) 1.04
IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol (2003) 1.04
The impact of PKR activation: from neurodegeneration to cancer. FASEB J (2014) 1.04
Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol (2007) 1.02
Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol (2004) 1.02
Antiviral action of the tumor suppressor ARF. EMBO J (2006) 1.02
Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One (2012) 1.01
Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun (2005) 1.01
Evidence that avian reovirus sigmaA protein is an inhibitor of the double-stranded RNA-dependent protein kinase. J Gen Virol (2003) 1.01
Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol (2009) 1.01
Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00
Therapeutics and vaccines against chikungunya virus. Vector Borne Zoonotic Dis (2015) 1.00
Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J Virol (2003) 1.00
F11-mediated inhibition of RhoA signalling enhances the spread of vaccinia virus in vitro and in vivo in an intranasal mouse model of infection. PLoS One (2009) 0.99
Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. J Biol Chem (2006) 0.98
Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol (2012) 0.98
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci U S A (2008) 0.98
Cryo X-ray nano-tomography of vaccinia virus infected cells. J Struct Biol (2011) 0.98
DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J Virol (2011) 0.97
A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol (2014) 0.97
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One (2012) 0.96
Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines (2013) 0.95
Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One (2011) 0.92
Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS One (2013) 0.92
Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine (2004) 0.92
Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J Immunol (2010) 0.92
Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant. Virol J (2005) 0.91
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol (2010) 0.91
A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLoS One (2011) 0.91
Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol (2008) 0.89
Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine (2010) 0.89
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS One (2012) 0.87
MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect (2006) 0.86
A vaccinia virus lacking A10L: viral core proteins accumulate on structures derived from the endoplasmic reticulum. Cell Microbiol (2006) 0.86
Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res (2005) 0.86
Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance. FEBS Lett (2002) 0.85
High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection. PLoS One (2012) 0.85
Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins. J Virol (2011) 0.85
Control of virus infection by tumour suppressors. Carcinogenesis (2007) 0.84
The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PLoS One (2011) 0.84
Activation of NF-kB pathway by virus infection requires Rb expression. PLoS One (2009) 0.84
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol (2014) 0.83
Wiskott-Aldrich syndrome protein is needed for vaccinia virus pathogenesis. J Virol (2005) 0.83
Membrane remodelling during vaccinia virus morphogenesis. Biol Cell (2009) 0.83
Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections. J Virol (2007) 0.83
Host-range restriction of vaccinia virus E3L deletion mutant can be overcome in vitro, but not in vivo, by expression of the influenza virus NS1 protein. PLoS One (2011) 0.82
Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection. Vaccine (2005) 0.82
A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PLoS One (2012) 0.80
Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergence. PLoS One (2011) 0.80
New vaccinia virus promoter as a potential candidate for future vaccines. J Gen Virol (2013) 0.80
Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein. J Immunol (2012) 0.79
Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector. Virol J (2008) 0.79
Virus infection rapidly activates the P58(IPK) pathway, delaying peak kinase activation to enhance viral replication. Virology (2011) 0.78